970x125
Have you heard of toad venom? It’s become much more than an esoteric drug favored by “psychonauts.” But supporters won’t have to lick a toad if the chemically synthesized and purified version becomes FDA-approved.
Toad “venom” is a defensive secretion, but both popular media and scientific literature refer to it as a “venom.” It is an ultra–short–acting serotonergic psychedelic, also known by its chemical name, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), that has recently entered early-stage pharmaceutical investigation.
Unlike most therapeutics, the toad venom pathway did not originate through traditional scientific/lab research. Instead, podcasts, celebrity testimonials, and viral media coverage piqued researchers’ interest. The experts learned that the natural substance produced by the Sonoran Desert toad, Incilius alvarius, from the American Southwest and northern Mexico, contained 5-MeO-DMT and other biologically active compounds. Secretions were collected, dried, and smoked by followers. The toad, formerly known by the scientific name Bufo alvarius, is among the largest native toads in North America, reaching eight inches.
Despite frequent claims of ancient religious origins, there’s no credible evidence for the historical use of toad secretions. Instead, modern use can be traced to late twentieth-century descriptions of extraction and administration of the substance, followed by information disseminated through underground psychedelic communities and, later, adoption in neo-shamanic practices. The terminology that emerged—“toad medicine,” “Bufo,” and “the God molecule”—reflects a cultural reframing that emphasizes spiritual and transformative narratives over pharmacological identity.
5-MeO-DMT is classified by the Drug Enforcement Administration (DEA) as a Schedule I controlled substance. But, around 2019–2021, former world champion fighter Mike Tyson described experiences with “toad” as life-altering, explicitly attributing improvements in his depression, trauma, and addiction to its use.
Additional figures across entertainment and athletics echoed similar narratives through platforms like Joe Rogan’s podcast, reinforcing a consistent message: A brief, highly intense, and uniquely potent psychedelic experience with toad venom could yield therapeutic benefits. Appearances on massive platforms like the Joe Rogan Experience and features in publications like The New York Times and GQ moved the conversation into the mainstream. Via its media-driven dissemination, toad bypassed the traditional bench-to-bedside drug pipeline, generating a large surge in demand manifested in retreat models, “toad ceremonies,” and informal therapeutic uses outside regulated healthcare systems.
As demand increased, some began to worry about the toads, and the National Park Service issued warnings about legal, safety, and ecological harms. Increased toad hunting led to its population decline and raised concerns about sustainability and animal welfare. The same cultural visibility accelerating the adoption of toad secretions also triggered environmental and public health scrutiny. Mainstream drug researchers became even more curious.
Recent early clinical trials of purified synthesized 5-MeO-DMT marked a real-time transition from lore to scientific inquiry. A large-scale neuroimaging mega-analysis newly published in Nature Medicine by Manesh Girn and colleagues demonstrates that psychedelics display a consistent “network fingerprint” of brain circuit connectivity, reconfiguring large-scale brain networks, and may improve depression and other illnesses.
Risks
From a safety standpoint, risks associated with self-administration of toad-derived secretions are serious. In addition to 5-MeO-DMT, the secretions contain bufotoxins, substances with potential cardiotoxic effects. Unsupervised use has been linked with intense psychological distress, including panic, paranoia, and destabilization, as well as physical injury. In uncontrolled settings, risks are substantial, deriving from variability in dosing, lack of oversight, and absence of structured support.
Such limitations led to the creation of synthetic 5-MeO-DMT, a pharmacologically defined intervention. 5-MeO-DMT was first synthesized in 1936 by Japanese chemists Hoshino and Shimodaira. Depending on the route of administration, the acute effects of 5-MeO-DMT’s may begin within 30 seconds and end, often, within 20 minutes (vaporization route).Taken by insufflation or intramuscular [IM] injection routes, effects begin within three to five minutes and subside within 45 to 60 minutes. Intranasal and vaporized preparations, are currently under investigation and meet the standards required for clinical therapeutics.
Psychedelics Essential Reads
Clinical Trials
In controlled clinical environments, where dosing is standardized and patients are screened and monitored, the new compound appears to be generally well-tolerated, with transient adverse effects such as nausea, headache, and intense, time-limited psychological experiences.
Phase-1 and 2 studies, including vaporized formulations of the substance, such as GH001, demonstrated rapid and substantial reductions in depressive symptoms, with some patients achieving remission in days. The effects emerged far more quickly than with conventional antidepressants, typically requiring at least weeks. The findings suggest that 5-MeO-DMT may operate through an entirely different therapeutic mechanism than most antidepressants.
The short duration of action represents a significant advantage. Unlike psychedelic-assisted therapies requiring multiple prolonged sessions, 5-MeO-DMT interventions can be completed in under an hour.
Race Towards FDA Approval
The two leading 5-MeO-DMT programs—conducted by Atai Life Sciences with Beckley Psytech (BPL-003) and GH Research (GH001)—have both shown rapid, clinically-meaningful antidepressant effects in mid-stage trials, supporting brief (two hour) in-clinic treatment. BPL-003 uses an intranasal, fixed-dose approach with optional repeat dosing, emphasizing standardization, durability, and potential for integration into psychiatric practice.
In contrast, GH001 is inhaled with intra-session dose escalation to achieve a full psychedelic effect in a single visit. The approach prioritizes acute efficacy; notably, effects occur within minutes and have produced significant symptom reductions within days.
Both programs are advancing toward Phase-3 development, positioning 5-MeO-DMT as a leading candidate in the next generation of rapid-acting psychiatric therapeutics. Researchers are investigating whether a “full mystical experience” is necessary for efficacy and how long the benefits last after a single dosing day. They also want to determine whether patients reach full remission, not just response.
Beyond treatment-resistant depression, ongoing/planned studies are asking whether synthesized toad venom works in major depressive disorder, postpartum depression, PTSD, and substance use disorders such as alcohol use disorder (AUD).
Summary
Can a single, minutes-long psychedelic exposure produce rapid, lasting antidepressant remission with a safe, scalable outpatient protocol? 5-MeO-DMT has moved from anecdotal evidence to high-impact early clinical trials. Phase-3 trials are needed to see whether and how this new treatment translates into a safe, clinically meaningful therapeutic tool. If it does, many can be grateful for the Sonoran Desert toad, where it all started.
